Priority Date: 01.09.10 (US 20100379197P)

PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS)

  • Application ID: EP11719705
  • Status: APPLICATION DEEMED TO BE WITHDRAWN

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC class C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Novartis Pharma AG is specialised in C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 01.09.2010 - Priority Date (US 20100379197P)
  • 03.11.2011 - Publication A1 (WO2011137206)
  • 06.03.2013 - Publication A1 (EP2563934)

IPC Classification